NCT06551584招募中1 期
Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Proportion of Patients Without Severe Transplant-Related Adverse Events at Day +100
研究概览
简要总结
The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible diseases:
- •Acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) as defined in Section 6.1.3; with or without the presence of known minimal residual disease, or
- •Myelodysplasic syndrome (MDS) myelodysplastic syndromes eligible for alloHSCT and/or treatment-related MDS <10% blasts
- •Age ≥ 18 and ≤ 70 years at the time of enrollment.
- •Eligible for myeloablative alloHCT including one of two the myeloablative conditioning regimens (fractionated total body irradiation plus cyclophosphamide or busulfan, fludarabine, and thiotepa)
- •Has a related or unrelated donor available who is 7/8 match (single allele mismatched) at HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods.
- •Estimated glomerular filtration rate (eGFR) ≥ 50 mL/minute or creatinine < 2 mg/dL.
- •Cardiac ejection fraction at rest ≥ 45% or shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA).
- •Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%.
- •Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included once hemolysis has been excluded).
- •Ability to understand and the willingness to provide written informed consent.
- •Negative serum or urine beta-HCG test in females of childbearing potential (FCBP) within 3 weeks of enrollment.
- •A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- •Able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent.
- •Karnofsky Performance Score ≥70%
排除标准
- •Prior allogeneic HCT.
- •Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.
- •Planned donor lymphocyte infusion (DLI).
- •Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy), peri-transplant anti-thymocyte globulin (ATG), or alemtuzumab. For patients that have previously been exposed to a T cell-depleting agent, a 5 half-life washout of the agent must occur prior to planned Day 0 (day of infusion of Orca-T HSPC and Tregs ).
- •Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:
- •Positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
- •Presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) >1000 by solid phase immunoassay.
- •Uncontrolled bacterial, viral, or fungal infections (currently taking antimicrobial therapy and with progression or no clinical improvement) at time of enrollment including known, active tuberculosis infection.
- •Seropositive for HIV-1 or -2, HTLV-1 or -2, Hepatitis B sAg, and/or Hepatitis C antibody.
- •*History of hepatitis B or hepatitis C is permitted if viral load is undetectable per quantitative PCR and/or NAT. In this case, monitoring for hepatitis B or hepatitis C by PCR at 3, 6, and 12 months is recommended.
- •Known allergy or hypersensitivity to, or intolerance of, any investigational agent or ingredient therein, or planned GVHD prophylactic medications.
- •Documented allergy or hypersensitivity to iron dextran or bovine, murine, algal or Streptomyces avidinii proteins.
- •Any uncontrolled autoimmune disease requiring active immunosuppressive treatment.
- •Concurrent malignancy diagnosed within 12 months of enrollment, except non-melanoma skin cancers that have been curatively resected.
- •Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use effective forms of birth control or abstinence for one year after transplantation.
- •(FCBP definition: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
- •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment. History of stroke or pulmonary embolism within 6 months of enrollment.
- •Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the recipient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results.
研究组 & 干预措施
ORCA-T + (tacrolimus and ruxolitinib)
Experimental
Dual-agent tacrolimus starting on the day after Tcon infusion (Day +3 or Day +4) and ruxolitinib starting on the day after tacrolimus (Day +4 or Day +5).
干预措施: ORCA-T (Drug)
结局指标
主要结局
Proportion of Patients Without Severe Transplant-Related Adverse Events at Day +100
时间窗: 18 months
The proportion of patients who, at Day +100 have not experienced any severe transplant-related adverse events including non-relapse mortality (NRM), primary graft failure, acute GVHD (grade 2-4), acute GVHD grade 3-4, or opportunistic infections (grade 4-5).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesAcute Lymphoid LeukemiaMyelodysplastic SyndromesBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Myeloid LeukemiaAcute Myeloid LeukemiaAcute LeukemiaNCT04013685Orca Biosystems, Inc.155
终止
2 期
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant PatientsChronic Myelogenous Leukemia, BCR-ABL1 PositiveDiffuse Large B-Cell LymphomaGraft Versus Host DiseaseChronic Lymphocytic LeukemiaMarginal Zone LymphomaMyeloproliferative NeoplasmSmall Lymphocytic LymphomaMyelodysplastic SyndromeAcute LeukemiaFollicular LymphomaMyelofibrosisMantle Cell LymphomaNCT02877082Emory University5
招募中
2 期
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell TransplantMyeloproliferative DisordersMyelodysplastic SyndromeAcute LeukemiaNCT06265584University of Alabama at Birmingham56
已完成
1 期
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaEssential ThrombocythemiaPolycythemia VeraNCT02407080John Mascarenhas13
已完成
1 期
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04742101Institut de Recherches Internationales Servier57